Navigation Links
Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
Date:10/2/2007

EXTON, Pa., Oct. 2 /PRNewswire/ -- Othera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on novel, patient-administered products for ophthalmology, oncology, and inflammatory disease, has announced the appointment of Frederick R. Rickles, MD, FACP, as Chief Scientific Officer effective immediately. In this position, Dr. Rickles will lead the development, integration and execution of Othera's research and clinical development programs.

"We are delighted to welcome Dr. Rickles to the Othera team," said David Joseph, Chairman and CEO of Othera Pharmaceuticals, Inc. "His broad expertise in oncology, hematology (thrombosis), and pharmacology will serve Othera well as we pursue our goal of becoming a leading specialty pharmaceutical company. Othera's business strategy requires an important focus on product diversification and target selection, and, thus, we will benefit from his extensive background and expertise."

Commenting on his new position, Rickles said, "This is an outstanding opportunity to join a specialty pharmaceutical company at a very important strategic stage of the organization. I believe that Othera's novel molecules and extensive intellectual property gives us the flexibility to build our future portfolio and create a broad growth platform, and I am delighted to have a key role in that effort."

Rickles, a 37-year veteran of the Medical Community, presently serves as a Fellow in the Center for Science and Technology, Healthcare Division of Noblis, a non-profit organization that works in the public interest. Among other important healthcare projects, Noblis helped the Centers for Medicare and Medicaid Services (CMS) implement Medicare Part D. Dr. Rickles has been working on a number of healthcare policy issues for Noblis, including pharmacovigilance, with a consortium of public and private stakeholders. Additionally, he has served as Associate VP/Health Research at The George Washington University (GWU) and was t
'/>"/>

SOURCE Othera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. TomoTherapy opens technical training center
3. TomoTherapy raises $223 million in IPO
4. TomoTherapy revises IPO money target
5. Hospital named for Madame Curie installs TomoTherapy system
6. TomoTherapy files registration statement for IPO
7. TomoTherapy to sell medical devices in India
8. TomoTherapy sees sustained market advantage
9. TomoTherapys 100th radiology system reaches public sector
10. TomoTherapy extends reach to Germany
11. Cash-rich TomoTherapy has no plans for IPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... India Solid Waste Management Vehicles Market Forecast ... In India ... responsible for complete handling and regulation of solid ... 135,000 MT solid waste is generated daily in ...
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... Innovation, Inc. (BHI), a regional private-public partnership focusing ... early-stage funding in Central Maryland, announced today the appointment ... at Qiagen , to its Board of ... to our board," said Scott Carmer, BioHealth Innovation, Inc. ...
... by Kathleen Eggleson, a research scientist in the Center ... of Notre Dame, provides an example of a nanotechnology-related ... The world of nanotechnology, which involves science and ... But like most new advances, the application of that ...
... On April 19, 2012, GeneLink,s common stock began trading ... this will be temporary as it is due to the ... for the period ended December 31, 2011.  The Company anticipates ... on Form 10K for the period ended December 31, 2011 ...
Cached Biology Technology:BioHealth Innovation, Inc. Appoints Qiagen's Douglas Liu to Board of Directors 2Notre Dame paper examines nanotechnology-related safety and ethics problem 2Notre Dame paper examines nanotechnology-related safety and ethics problem 3GeneLink Anticipates Completion of Audit 2
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... the same DNA sequence their genetic information. How ... in the different parts of the body are so ... master plan, an additional regulatory layer exists that determines ... This mechanism involves modifications of genome-bound histone proteins or ... It acts on top of the genetic information and ...
(Date:9/2/2014)... the September issue of The FASEB Journal ... to diagnose the leading cause of blindness in ... occurred. This advance involves quantifying the early molecular ... retinal vessels. Using new probes developed by scientists, ... development of diabetic retinopathy. , "My goal is ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... Scientists have discovered that a stem cell factor overexpressed ... brain injury promotes tumor survival by inducing angiogenesis. The ... Cell, examines the interaction between tumor cells and surrounding ... more effective therapeutics for one of the most lethal ...
... In an unexpected discovery, scientists at Jefferson Medical College ... virus protein can turn a "safe" virus extremely deadly. ... vaccine they previously created against rabies in wildlife, making ... a molecular mechanism involved in making the rabies virus ...
... disease in the brain of the fruit fly, researchers ... proteins previously associated with cancer. , The findings are ... Brigham and Women's Hospital, Harvard Medical School, and the ... not divide. It is therefore perplexing that in Alzheimer's ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Jefferson researchers building a better rabies vaccine 2
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: